Peptide Regulation & Safety (class)

Testimony presented by the AAPM at the FDA's PCAC meeting covered pharmacy dispensing records for more than 16 million doses of BPC-157 over 9 years. Seven adverse events were reported back to pharmacies, all mild, and most were injection site reactions. This is the largest real-world exposure dataset available for the compound and it is a matter of public record. Cited as the direct rebuttal to the claim that BPC-157 has no human safety characterization.

Physicians cannot legally prescribe growth hormone off-label in the United States; doing so exposes the prescriber to felony liability under the 1990 Anabolic Steroid Control Act. This is the practical reason GHRH analogs such as CJC-1295 and tesamorelin are used in place of growth hormone, and it undercuts the argument that patients should simply take growth hormone instead.

Rebuttal to the argument that VEGF and nitric oxide signaling make peptides tumor-promoting. Growth hormone carries a more direct pro-growth mechanism, has decades of market exposure, and has never shown a cancer signal. Exercise and sauna also increase blood flow and angiogenic signaling. The same reasoning was used to restrict off-label growth hormone in 1990.

The 2013 Supreme Court ruling against Myriad Genetics held 9-0 that DNA segments, and by extension naturally occurring products of that DNA including native peptide sequences, are not patent eligible. Salt, process and delivery-system patents remain available but a competent competitor can design around a process patent in roughly 18 months. No sponsor funds a $500 million to $1 billion registrational program without composition-of-matter exclusivity. Combined with small addressable indications, the absence of a big-pharma race reflects patent economics rather than evidence of failure.

DIP, studied for opioid and alcohol withdrawal with human trial data on safety and efficacy, was the single peptide at the PCAC meeting not to receive a positive vote. The FDA's argument was that approved alternatives already exist. The two most prescribed options for opioid withdrawal are methadone, attributed roughly 3,400 deaths per year, and buprenorphine/naloxone, attributed at least 1,500.

At the FDA's Pharmacy Compounding Advisory Committee meeting, six of the seven peptides reviewed received a positive vote. Compounded peptides are evaluated under the 503A pathway rather than the IND pathway written for commercially sold new drugs, a distinction often omitted when the two standards are compared.

The average drug administration period in a US phase 1 trial is 16 days, though participants are monitored for 12 to 13 months. Meaningful safety signal therefore does not emerge until phase 2, phase 3, or post-market surveillance. Relevant when comparing a new synthetic drug's trial safety package against multi-year real-world peptide dispensing data.

Structural critique of the five-question screening framework applied to peptides: it treats mechanism and human outcome data as both being mandatory, so a single no ends the assessment. In regulatory practice either one can carry a drug. Applying the framework as an AND gate would disqualify a large share of the existing pharmacopoeia.

Section 505(d) of the Food, Drug and Cosmetic Act requires substantial evidence of effectiveness plus adequate safety data. It does not mention mechanism of action. Approved drugs whose mechanism remains unresolved include tadalafil for BPH, intravesical BCG for bladder cancer (approved 1990), acetaminophen (now attributed to the AM404 metabolite acting on cannabinoid receptors rather than COX inhibition), SSRIs, and general anesthesia. Aspirin was used for roughly 70 years before its prostaglandin mechanism was described in 1971.

BPC-157, TB-500, Epitalon and KPV were legally manufactured and distributed through US compounding pharmacies for at least 9 years before the FDA restricted them in 2023. Dispensing and adverse event data across that period was presented at the PCAC meeting and shows a consistent pattern of low reported harm across all four compounds.

Framing argument for judging peptide risk in context: the observed adverse event rate across millions of dispensed peptide doses is presented as more favorable than ibuprofen, which is attributed roughly 16,500 deaths per year in the United States. The point is that risk is comparative, and that peptides are frequently held to a standard no common analgesic would meet.